Vijay Kannuthurai, MD
Rheumatology · Saint Louis, MONPI 1669967527
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,212 of the $3,842 with a category attached, or 83.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,295 and has fallen 52.8% since, to $1,083 in 2025.
Across 151 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$902
- AbbVie$777
- Amgen$471
- AstraZeneca$305
- Novartis$247
- UCB, Inc.$228
- plus $913 from 15 others
What the payments were for
- Consulting fees$63016%
- Food & beverage$3,21284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $902 |
| AbbVie | 40 | $777 |
| Amgen | 23 | $471 |
| AstraZeneca(2 entities) | 14 | $305 |
| Novartis | 13 | $247 |
| UCB, Inc. | 10 | $228 |
| Lilly USA, LLC | 3 | $156 |
| ANI Pharmaceuticals, Inc. | 3 | $153 |
| GSK | 8 | $152 |
| Sanofi | 4 | $82 |
| Sobi, Inc | 3 | $76 |
| Pfizer | 3 | $61 |
| Fresenius Kabi USA, LLC | 3 | $51 |
| Octapharma USA, Inc. | 2 | $34 |
| Organon | 3 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Invivyd Inc | 1 | $22 |
| Sandoz | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$630
- ZEPBOUND$123
- KRYSTEXXA$122
- PURIFIED CORTROPHIN GEL$116
How this compares
$3,842 in reported general payments places this provider in the 60th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 147 | $4,068 |
| MethotrexateMethotrexate Sodium | 97 | $1,799 |
| Leflunomide | 31 | $1,012 |
| Pilocarpine Hcl | 18 | $914 |
| Celecoxib | 54 | $710 |
| Azathioprine | 16 | $664 |
| Prednisone | 107 | $414 |
| Colchicine | 14 | $339 |
| Folic Acid | 26 | $257 |
| Meloxicam | 22 | $46 |
| Allopurinol | 30 | $39 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Saint Louis
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Sona KamatSaint Louis$268K
- Richard BrasingtonSaint Louis$100K
- Akgun InceSaint Louis$45K
- Joseph StauberSaint Louis$37K
- Alissa ChandlerSaint Louis$37K
- Chad RonholmSaint Louis$27K
- Sandra HoffmannSaint Louis$23K
- John BuddSaint Louis$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.